Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

NCT00681863 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated for slow enrollment.

Conditions

Tourette Syndrome

Interventions

DRUG: pramipexole 0.125 mg BID
DRUG: pramipexole 0.0625 mg QD
DRUG: pramipexole 0.125 mg TID
DRUG: pramipexole 0.25 mg BID
DRUG: pramipexole 0.0625 mg BID

Sponsor

Boehringer Ingelheim